Hepatic myelopathy after transjugular intrahepatic portosystemic shunt:natural course,survival analysis,and treatment
-
摘要: 目的研究经颈静脉肝内门体分流术(TIPS)后肝性脊髓病(HM)的特征。方法回顾性纳入第四军医大学西京消化病医院消化介入科2005年-2014年肝硬化门静脉高压经TIPS手术成功治疗后发生HM的连续病例。所有患者于TIPS术后1、3、6个月以及之后每半年进行常规随访。根据疾病进展时间总结HM的自然病程,计量资料组间比较采用独立样本t检验;计数资料组间比较采用χ2检验。通过Kaplan-Meier法进行生存分析,并用Cox比例风险回归模型筛选其预后的预测因素,统计患者下肢症状缓解情况以分析其治疗效果。结果从HM 1级发展到2、3、4级的时间分别为4.0(136)个月、8.5(144个月和18.87(5.448.6)个月。HM患者1、3和5年累计生存率分别为84.19%、51.86%和45.21%。HM发病年龄[风险比(HR)=1.034,95%可信区间(95%CI):1.0031.065]和再发腹水(HR=3.869,95%CI:1.6239.225)是HM患者预后的独立预测因素。...
-
关键词:
- 肝硬化 /
- 高血压,门静脉 /
- 肝性脊髓病 /
- 门体分流术,经颈静脉肝内
Abstract: Objective To investigate the features of hepatic myelopathy(HM) after transjugular intrahepatic portosystemic shunt(TIPS).Methods A retrospective analysis was performed for a consecutive cohort of patients with cirrhotic portal hypertension who were successfully treated with TIPS in Department of Liver Disease and Digestive Interventional Radiology in Xijing Hospital of Digestive Diseases,Fourth Military Medical University,from 2005 to 2014 and then developed HM.Routine follow- up was performed for all patients at 1,3,and 6months after TIPS and every half a year subsequently.The time to disease progression was used to summarize the natural course of HM,the comparison of continuous data was made by independent samples t- test,the comparison of categorical date was made by chi- square test.The Kaplan- Meier method was used for survival analysis,and the Cox proportional hazards regression model was used to determine prognostic factors.Relief of symptoms in the lower limbs was analyzed to investigate the therapeutic effect.Results The time to HM progression from grade 1 to grades 2,3,and 4 was 4.0 months(range,1- 36 months),8.5 months(range,1- 44 months),and 18.8 months(range,5.4- 48.6 months),respectively.In HM patients,the 1-,3-,and 5- year cumulative survival rates were 84.19%,51.86%,and 45.21%,respectively.Age of HM onset(HR = 1.034,95% CI:1.003- 1.065) and recurrent ascites(HR = 3.869,95% Cl:1.623- 9.225) were independent prognostic factors in patients with HM.The patients who underwent liver transplantation had a significantly higher proportion of patients with relief of symptoms than those who did not undergo liver transplantation(χ2= 13.5,P = 0.003),while the effects of stent flow limitation and occlusion showed no significant differences(P > 0.05).Conclusion The course of HM consists of rapid progression stage and plateau stage,and HM patients after TIPS show good survival.At present,liver transplantation is an effective method to treat HM.-
Key words:
- liver cirrhosis /
- hypertension /
- portal /
- hepatic myelopathy
-
[1]BAJAJ JS.Liver capsule:hepatic encephalopathy[J].Hepatology,2015,62(3):955. [2]TIBERI O,TOGNARELLI JM,COOK NA,et al.Diagnosing and treating hepatic encephalopathy[J].Br J Hosp Med(Lond),2015,76(11):646,648-652,654. [3] ELLUL MA,GHOLKAR SA,CROSS TJ.Hepatic encephalopathy due to liver cirrhosis[J].BMJ,2015,351:h4187. [4]CORDOBA J.New assessment of hepatic encephalopathy[J].J Hepatol,2011,54(5):1030-1040. [5]LALEMAN W,SIMON-TALERO M,MALEUX G,et al.Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy:a multicenter survey on safety and efficacy[J].Hepatology,2013,57(6):2448-2457. [6]MOORE KP,WONG F,GINES P,et al.The management of ascites in cirrhosis:report on the consensus conference of the International Ascites Club[J].Hepatology,2003,38(1):258-266. [7]NARDONE R,HOLLER Y,STORTI M,et al.Spinal cord involvement in patients with cirrhosis[J].World J Gastroenterol,2014,20(10):2578-2585. [8] KORI P,SAHU R,JAISWAL A,et al.Hepatic myelopathy:an unusual neurological complication of chronic liver disease presenting as quadriparesis[J].BMJ Case Rep,2013.pii:bcr2013-009078. [9] PANICKER J,SINHA S,TALY A,et al.Hepatic myelopathy:a rare complication following extrahepatic portal vein occlusion and lienorenal shunt[J].Neurol India,2006,54(3):298-300. [10]D'AMICO G,GARCIA-TSAO G,PAGLIARO L,et al.Natural history and prognostic indicators of survival in cirrhosis:a systematic review of 118 studies[J].J Hepatol,2006,44(1):217-231. [11]ZHAO HW,LIU FQ,YUE ZD,et al.Clinical effects of transjugular interventional stent-shunt therapy in hepatic myelopathy after transjugular intrahepatic portosystemic shunt[J].Chin J Radiol,2013,47(3):239-244.(in Chinese)赵洪伟,刘福全,岳振东,等.经颈静脉途径介入干预经颈静脉肝内门体静脉分流术分流后肝性脊髓病的临床疗效[J].中华放射学杂志,2013,47(3):239-244. [12]CALDWELL C,WERDIGER N,JAKAB S,et al.Use of model for end-stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literature[J].Liver Transpl,2010,16(7):818-826.
计量
- 文章访问数: 287
- HTML全文浏览量: 34
- PDF下载量: 169
- 被引次数: 0